Myeloma Profile

+5 / +9 / +15, del 13q14.3, p53 del 17p13.1, IGH 14q32

F MM

Test Synonym:

Multiple myeloma

Associations:

Myeloma

CPT Code:

88367x7 – Morphometric analysis, in situ hybridization, automated
88368x7 – Morphometric analysis, in situ hybridization, manual

Turnaround Time:

3 days

Methodology:

Fluorescence in situ Hybridization (FISH)

Specimen Requirements:

2.0 ml (min. 1.0 ml) peripheral blood in sodium heparin preferred, EDTA accepted

1.0 ml (min. 0.5 ml) bone marrow in sodium heparin preferred, EDTA accepted

5 mm3 fresh tissue in MPLN RPMI media

3.0 ml (min. 2.0ml) FNA in MPLN RPMI media

10% neutral buffered formalin fixed paraffin embedded tissue

Causes for Rejection:

Clotted specimen; specimens exposed to extreme temperature; anticoagulant toxic to cells; insufficient number of cells; improper fixative

Specimen Stability:

Peripheral blood and bone marrow stable at 18-25°C for 72 hours

Fresh tissue or FNA stable at 2-8°C for 72 hours

Storage and Handling:

Whole blood and bone marrow ship ambient

Fresh tissue, FNA or paraffin embedded tissue ship in a Styrofoam container with an ice pack (do not allow ice pack to directly contact sample)

Reference Range:

See report

Indication:

Aneuploidy is a frequent finding in plasma cell myeloma.  Approximately 60-70% of myeloma cases have been reported to have hyperdiploid clones.  About 10-20% have been reported to have pseudodiploid clones, and 10-30% have been reported to have hypodiploid clones. The most frequent cytogenetic abnormalities are 13q13~q14 deletions and translocations involving the immunoglobulin heavy chain (IGH) gene on 14q32, most frequently t(11;14), t(4;14), and t(14;16) whereas 17p13 deletions are rare.  FISH can detect these abnormalities in either interphase or metaphase cells.

References:

1. Christensen, Jacob et al. (2007) Cancer Genetics and Cytogenetics 17489-99
2. Schmidt-Wolf I.G.H., et al. (2006) Cancer Genetics and Cytogenetics 167 20–25